Patient Profiles and Distribution of Disease
| Patient no. | Age at diagnosis (y) | Sex | Weight (kg) | Primary site | Administered activity (MBq) | Tumor absorbed dose (cGy) | Metastases at presentation | History before 186Re-HEDP |
|---|---|---|---|---|---|---|---|---|
| 1 | 16 | M | 50 | L tibia | 2,820 | 2.3 | No | Ifosfamide; amputation; metastasectomy; lobectomy at 8 y; large bony secondary at 10 y |
| 2 | 21 | F | 65 | Sacrum | 1,410 | 16 (hip) and 9 (knee) | No | Doxorubicin + cisplatin × 4; progression of primary tumor and lung, bone, and intraabdominal metastases |
| 3 | 24 | M | 58.5 | Pelvis | 5,310 | 3.1 | No | Doxorubicin + cisplatin; progression; etoposide + cisplatin; excision; margin positive; ifosfamide; EBRT: 50 Gy per 11.3 kg (25 fractions) of body weight, paravertebral relapse; HDMTX |
| 4 | 12 | F | 40 | Ilium | 1,350 | 1.60 and 3.1 | No | Cisplatin + ifosfamide (later omitted) + etoposide × 4; HDMTX × 2; good response by primary tumor but pulmonary progression; primary tumor inoperable |
| 5 | 22 | F | 61 | Distal femur | 1,296 | 2.4 | No | Doxorubicin + cisplatin + etoposide; distal femoral replacement; local, nodal, and pulmonary progression at 14 mo |
| 6 | 42 | F | 74 | Sacrum | 1,420 | 0.5–0.6 (4 sites) | No | Doxorubicin + cisplatin/carboplatin × 6 |
| 7 | 14 | M | 54 | Tibia | 1,430 | 2 | No | Doxorubicin + cisplatin × 6; amputation; bone metastasis; HDMTX; ifosfamide; further bone disease |
| 8 | 12 | M | 45 | Tibia | 1,399 | 2, 2, and 5 (3 sites) | No | Doxorubicin + cisplatin × 6; amputation; pulmonary metastasis at 2 y; metastasectomies; further pulmonary relapse; HDMTX; ifosfamide |
| 9 | 16 | M | 44 | Distal femur | 2,660 | 1.4 and 2.2 | No | Doxorubicin + cisplatin × 6; endoprosthetic replacement; pulmonary, mediastinal, and pleural relapse at 8 mo; ifosfamide + etoposide × 5; partial remission |
| 10 | 16 | M | 55.2 | Proximal humerus | 1,182 | 14 | No | Doxorubicin + cisplatin × 6; disarticulation; adjuvant EBRT to supraclavicular fossa; pulmonary and pleural relapse at 72 mo; metastasectomy and pleurectomy; HDMTX; ifosfamide; etoposide; progressive disease |
| 11 | 12 | M | 32 | Femur | 1,400 | 1.1 and 2.0 | Yes | Doxorubicin + cisplatin × 2; HDMTX; lung progression; endoprosthetic replacement; high-dose ifosfamide (12–14 g/m2) + etoposide × 3; progressive lung and bone disease |
| 12 | 16 | M | 49 | Femur | 1,430 | 1.4 | No | Doxorubicin + cisplatin × 6, pleural recurrence; resection; ifosfamide + etoposide + MTX; bowel recurrence resected; internal mammary nodes eroding chest wall |
| 13 | 27 | M | 55 | Ilium + sacrum | 1,500 | 16 | No | Doxorubicin + cisplatin + HDMTX; then ifosfamide + etoposide; EBRT to right pelvis; deposit L5 vertebra |
HDMTX = high-dose methotrexate.